Renal failure late after liver transplantation

Liver Transplantation

Volumn 8, Issue 10, 2002, Pages 922-924

  Neuberger, James ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CREATININE; CYCLOSPORIN; EDETIC ACID; FINGOLIMOD; IMMUNOSUPPRESSIVE AGENT; INULIN; LEFLUNOMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PENTETIC ACID; RAPAMYCIN; TACROLIMUS; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR;

ALLOGRAFT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; EDITORIAL; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; LIVER TRANSPLANTATION; LONG TERM CARE; MUSCLE MASS; NEPHROTOXICITY; NUTRITION; PRIORITY JOURNAL; RISK ASSESSMENT; SIDE EFFECT;

EID: 0036793295     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2002.35669     Document Type: Article

References (15)

1. Gonwa TA, Mai ML, Melton LB, Hays SR, Goldstein RM, Levy MF, Klintmalm GB. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurine-based immunotherapy: risk of development and treatment. Transplantation 2001;72:1934-1939.
2. Fisher NC, Nightingale PG, Gunson BK, Lipkin GW, Neuberger JM. Chronic renal failure following liver transplantation: A retrospective analysis. Transplantation 1998;66:59-66.
3. Lynn M, Abreo K, Zibari G, McDonald J. End-stage renal disease in liver transplants. Clin Transplant 2001;15(suppl 6):66-69.
4. Cohen AJ, Stegall MD, Rosen CB, Wiesner RH, Leung N, Kremers WK, Zein N. Chronic renal dysfunction late after liver transplantation. Liver Transpl 2002;8:916-921.
5. Okabe H, Yano I, Hashimoto Y, Saito H, Inui K. Evaluation of increased bioavailability of tacrolimus in rats with experimental renal dysfunction. J Pharm Pharmacol 2002;54:65-70.
6. Jain S, Bicknell GR, Nicholson ML. Tacrolimus has less fibrogenic potential than cyclosporin A in a model of renal ischaemia-reperfusion injury. Br J Surg 2000;87:1563-1568.
7. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16;31-46.
8. Orlando R, Floreani M, Padrini R, Palatini P. Evaluation of measured and calculated creatinine clearances as glomerular filtration markers in different stages of liver cirrhosis. Clin Nephrol 1999;51:341-347.
9. Lam NP, Sperelakis R, Kuk J, Seeger JD, Lau AH. Rapid estimation of creatinine clearances in patients with liver dysfuntion. Dig Dis Sci 1999;44:1222-1227.
10. Stewart SF, Hudson M, Talbot D, Manas D, Day C. Mycophenolate mofetil monotherapy in liver transplantation. Lancet 2001;357:609-610.
11. Papatheodoridis GV, O'Beirne J, Mistry P, Davidson B, Rolles K, Burroughs AK. Mycophenolate mofetil monotherapy in stable liver transplant patients with cyclosporine-induced renal impairment: a preliminary report. Transplantation 1999; 68:155-157.
12. Herrero JL, Quiroga J, Sangro B, Girala M, Gomez-Manero N, Perdo F, et al. Conversion of liver transplant recipients on cyclesporine with renal impairment to mycophenolate mofetil. Liver Transpl Surg 1999;5:414-420.
13. Barkmann A, Nashan B, Schmidt HH, Boker KH, Emmanouilidis N, Rosenau J, et al. Improvement of acute and chronic renal dysfunction in liver transplant recipients after substitution of calcineurin inhibitors by mycophenolate mofetil. Transplantation 2000;69:1886-1890.
14. Nour B, Egidi MF, Cowan PA, Sebastian A, Shokouh-Amiri MH, Vera SH, Gaber A. Safety and effectiveness of conversion to sirolimus in liver transplant recipients with renal dysfunction [abstract]. Am J Transpl 2002;(suppl 3):462.
15. Coopersmith CM, Brennan DC, Miller B, Wang C, Hmiel P, Shenoy S, et al. Renal transplantation following previous heart, liver and lung transplantation: An 8-year single-center experience. Surgery 2001;130:457-462.